Publications by authors named "A Serris"
Mucormycosis is a fungal infection typically affecting immunocompromised patients. Here, we report a severe case of invasive cutaneous and peritoneal mucormycosis caused by Rhizopus microsporus, successfully treated with a combination of antifungal therapy, PD-1 inhibitor, and interferon-gamma. We highlight the importance of personalized immunotherapy in refractory cases of invasive mucormycosis.
View Article and Find Full Text PDFIntroduction: Cabotegravir, an integrase strand transfer inhibitor, and rilpivirine, an NNRTI, constitute the first long-acting (LA), injectable, two-drug ART regimen approved for the maintenance of virological suppression in persons living with HIV-1 (PLHIV). The aim of this study was to assess clinical effectiveness and tolerability of LA cabotegravir/rilpivirine in a real-world setting.
Patients And Methods: We conducted a retrospective, single centre study, including all PLHIV receiving LA cabotegravir/rilpivirine as standard-of-care in our tertiary centre even if initiated in clinical trials.
Article Synopsis
- A patient with HIV had serious eye problems from a virus called CMV because their medicine wasn't working anymore.
- Doctors tried different treatments, but they weren't successful, so they combined several medicines to try and help the patient.
- Even though the new treatment worked for a while, the patient still had to deal with a weakened immune system and problems with the virus coming back.
Article Synopsis
- Cerebral aspergillosis (CA) has a high mortality rate, and the study focuses on the effectiveness and safety of isavuconazole as a treatment option compared to standard therapies like voriconazole.
- An analysis of 40 patients treated with isavuconazole across 10 countries showed that the drug effectively controlled CA in about 70-73% of cases, with a 12-week mortality rate of 18%.
- The findings suggest that isavuconazole is well-tolerated and can provide similar survival outcomes to voriconazole, making it a viable first-line treatment option for CA.
Article Synopsis
- The COVID-19 pandemic has severely affected individuals with hematological malignancies due to their weakened immune systems, resulting in higher mortality rates and severe outcomes.
- Data from the EPICOVIDEHA registry, which compiles COVID-19 cases from these patients worldwide, was collected from 2020 to 2022, including 8,767 cases from 152 centers across 41 countries.
- Findings show a significant drop in critical infections and overall mortality rates, but hospitalization (especially in ICU) remains a serious risk factor; vaccination is linked to better survival outcomes, highlighting the need for ongoing monitoring and support for these patients.